{"id":"W4394565933","doi":"10.21203/rs.3.rs-4232431/v1","title":"Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"Genentech; H. Lundbeck A/S; Mitsubishi Tanabe Pharma Corporation; Deutsche Forschungsgemeinschaft; Eisai; Parkinson's UK; Prothena; Parkinson's Foundation; Parkinson Canada; Sunovion; Weston Brain Institute; F. Hoffmann-La Roche; EU Joint Programme – Neurodegenerative Disease Research; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries; Bristol-Myers Squibb; Eli Lilly and Company; Biogen; Michael J. Fox Foundation for Parkinson's Research","keywords":"Open label; Parkinson's disease; Extension (predicate logic); Physical medicine and rehabilitation; Medicine; Motor symptoms; Neuroscience; Psychology; Disease; Clinical trial; Internal medicine; Computer science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00247767,0.0006274804,0.0015586,0.0001705867,0.0003334361,0.0007818092,0.0003709621,0.0006902585,0.002153574],"category_scores_gemma":[0.002145036,0.0001731927,0.001340156,0.0001823125,0.0005191121,0.000766483,0.0003995426,0.001638309,0.0002703696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002446013,"about_ca_system_score_gemma":0.0004091692,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002283679,"about_ca_topic_score_gemma":0.00050454,"domain_scores_codex":[0.9991643,0.0004819463,0.00006060057,0.0001164504,0.00007674663,0.00009994119],"domain_scores_gemma":[0.9985083,0.0003976037,0.0004308015,0.0001727266,0.0001165725,0.0003741071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9501925,0.005094282,0.003908653,0.0005993053,0.001280828,0.0001006992,0.000107341,0.0004325158,0.005353323,0.0001895842,0.00087492,0.03186598],"study_design_scores_gemma":[0.6068603,0.3275869,0.05422166,0.0001793573,0.001787451,0.0003225924,0.000139857,0.001223079,0.003107649,0.0006018474,0.003920797,0.00004851831],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945006,0.003318775,0.0002216811,0.0001383661,0.000120954,0.0002519101,0.0003530578,0.00002848074,0.001066195],"genre_scores_gemma":[0.9976345,0.000598378,0.0002969735,0.0001427552,0.0001326584,0.0003265077,0.0004466058,0.000003870743,0.0004177857],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00247767,"threshold_uncertainty_score":0.01310337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07739333790851975,"score_gpt":0.4485825386472711,"score_spread":0.3711892007387513,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}